Omnicom retains Bristol Myers Squibb's US media account, expands mandate to HCP business

The pharmaceutical major has consolidated its US healthcare professional and direct-to-consumer media responsibilities with Omnicom following a competitive review

e4m by e4m Staff
Published: Nov 20, 2026 9:21 AM  | 2 min read
Omnicom Expands Media Role for Bristol Myers Squibb in 2027
  • e4m Twitter
  • Omnicom Media has retained Bristol Myers Squibb's US media account and gained additional healthcare professional media responsibilities after a competitive review, effective in 2027.
  • The account was previously managed by IPG Mediabrands and CMI Media Group, with a history of competitive agency reviews, including a shift from Havas to IPG in 2023.
  • The estimated media budget for BMS was approximately $430 million in 2023, though this figure does not reflect the value of the new mandate.
  • This retention and expansion strengthen Omnicom's position in pharmaceutical media advertising, following its recent acquisition of Interpublic Group and the awarding of Novo Nordisk's media business earlier this year.

Omnicom Media has retained pharmaceutical major Bristol Myers Squibb's (BMS) US media account following a competitive review, while also securing additional healthcare professional (HCP) media responsibilities. According to global reports, the expanded mandate will take effect in 2027.

The decision represents an important account retention for Omnicom following its acquisition of Interpublic Group (IPG). The business was previously handled by IPG Mediabrands, while WPP-owned CMI Media Group is understood to have managed the HCP media assignment.

The account has a history of competitive agency reviews. In 2023, IPG Mediabrands secured BMS's US media business from Havas. At the time, global reports reported that the pharmaceutical company's media budget stood at approximately $430 million, citing a request for information issued during the review. The figure relates to 2023 and does not represent the value of the latest mandate.

The latest development further strengthens Omnicom's position in pharmaceutical media advertising. Earlier this year, Novo Nordisk awarded its US media buying business to Omnicom, moving the account from WPP. According to reports, Novo Nordisk's annual media expenditure exceeded $600 million.

 For Omnicom, the BMS decision is significant as it combines the retention of an inherited IPG relationship with an expansion into additional specialist healthcare media responsibilities.

The development also comes amid continued consolidation and competitive realignment across global advertising holding companies following the Omnicom-IPG merger.

The financial value of the renewed BMS assignment and the specific Omnicom agency responsible for servicing the expanded account have not been publicly disclosed.

Published On: Nov 20, 2026 9:21 AM